Kyverna Therapeutics, Inc. (KYTX) analyst actions
Rating and price-target actions on KYTX in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the KYTX overview →
3 measured KYTX analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results | Press release | +5.13% | +4.76% | |
| Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025 | Press release | +5.20% | -0.89% | |
| Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS | Press release | +5.61% | +3.21% |
Keep exploring
More KYTX: earnings → · SEC filings → · KYTX overview →